Tinea: Clinical Trials

46 trials for Tinea, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

46 completed. 46 Phase 2, 3 Phase 3, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 246Completed 46
Phase 33Completed 3
Phase 12Completed 2

Follow Tinea: new trials by email Literature Review of Tinea trials Research Report on Tinea

Trials (filtered) newest first · largest first

All 46 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pilot Study of Swift Microwave Device for Onychomycosis
Swift Microwave treatment - weekly x 4wks, Swift Microwave treatment - Every other week x 4wks, Swift Microwave treatment - Every other week x 24wks - Onychomycosis of Toenail
Phase 1 / Phase 2CompletedMediprobe Research Inc.392023-03-272024-11-18
A Trial Involving Treatment of BB2603 in Subjects With Distal Subungual Onychomycosis of the Toenail
BB2603-1, BB2603-3, BB2603-10 - Distal Subungual Onychomycosis, Fungal Infection
Phase 2CompletedBlueberry Therapeutics1112021-03-222023-08-01
A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis
UHE-103A1 cream, UHE-103A2 cream, UHE-103B cream - Tinea Pedis
Phase 2CompletedTherapeutics, Inc.2402019-03-152021-10-28
A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis
Janthinobacterium lividum - Tinea Pedis
Phase 2CompletedDermBiont, Inc.122019-02-192025-06-17
Three-Arm Trial of Novel Treatment for Tinea Pedis
Experimental Drug SESC 01, Placebo, Terbinafine Hydrochloride - Tinea Pedis
Phase 2CompletedSouth End Skin Care902017-01-032017-10-06
Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete's Foot
Nitric Oxide, Water - Tinea Pedis
Phase 2CompletedNitric Solutions Inc.202016-08-132019-09-20
SB208 for the Treatment of Tinea Pedis
SB208 2%, SB208 4%, SB208 16% - Tinea Pedis
Phase 2CompletedNovan, Inc.2222016-07-192019-01-10
Efficacy, Safety, and Tolerability of HTS-519 Insert in Patients With Toenail Fungus of the Big Toenail
HTS-519 Insert - Onychomycosis
Phase 2CompletedHallux, Inc.302016-07-012021-11-02
Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study
NVXT topical, Placebo (Vehicle) Topical - Onychomycosis
Phase 2CompletedSun Pharmaceutical Industries, Inc.1842016-03-212018-12-20
Design and Clinical Evaluation of a School Meal With Deworming Properties
Ujiplus, Albendazole, uji - Helminthiasis, Tinea Capitis
Phase 2 / Phase 3CompletedKenya Medical Research Institute3262015-05-012016-09-07
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail
VT-1161, Placebo - Onychomycosis
Phase 2CompletedViamet2592015-02-172020-11-04
Evaluation of the Suitability of PD P 506 A in the PDT of Distal Subungual Onychomycosis (DSO) of the Great Toenail.
PD P 506 A - Onychomycosis
Phase 2Completedphotonamic GmbH & Co. KG252015-01-012017-09-19
Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail
NVXT Solution, Vehicle of test product - Onychomycosis
Phase 2CompletedSun Pharmaceutical Industries, Inc.472014-12-012018-09-19
Clinical Trial Comparing BL123 Versus Ketoconazole in Patients With Tinea Pedis
Dapaconazole, Ketoconazole - Tinea Pedis
Phase 2CompletedGilberto De Nucci602014-07-012016-07-07
Clinical Trial Comparing Dapaconazole Versus Miconazole in Patients With Tinea Cruris
Dapaconazole, Miconazole Nitrate - Tinea Cruris
Phase 2CompletedGaleno Desenvolvimento de Pesquisas Clínicas512014-01-292017-12-02
Efficacy and Safety Study of ME1111 in Patients With Onychomycosis
ME1111 Solution, Low strength, ME1111 Solution, High strength, Matching Vehicle Solution - Onychomycosis
Phase 2CompletedMeiji Seika Pharma Co., Ltd.3042013-12-192024-03-18
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis
VT-1161, placebo - Tinea Pedis
Phase 2CompletedViamet502013-08-012018-08-01
Evaluation of Preclinical Toxicity andTherapeutic Efficacy of Kandhaga Rasayanam in Padarthamarai
kandhaga rasayanam - Tinea Infections Such as Tinea Corporis, Tinea Cruris, Tinea Pedis, Tinea Mannum, Tinea Barbae, Tinea Capitis Are Studied
Phase 2CompletedNational institute of Siddha502012-06-012014-09-12
Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis
Luliconazole Solution, 10%, Vehicle Solution - Distal and Lateral Subungual Onychomycosis
Phase 2 / Phase 3CompletedTopica Pharmaceuticals3342012-05-012015-11-30
Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail
Terbinafine HCl - Onychomycosis
Phase 2CompletedNitric BioTherapeutics, Inc252011-12-012012-10-19

Showing 20 of 46. Sign in to see all of them.

Narrower conditions

Onychomycosis (30)  ·  Tinea Pedis (13)  ·  Mycoses (3)  ·  Tinea Cruris (2)  ·  Anemia (1)  ·  Communicable Diseases (1)  ·  Dermatomycoses (1)  ·  Foot Dermatoses (1)  ·  Foot Diseases (1)  ·  Helminthiasis (1)  ·  Infections (1)  ·  Pruritus (1)  ·  Skin Diseases (1)  ·  Tinea Capitis (1)

Broader conditions

Bacterial Infections and Mycoses (46)  ·  Skin Diseases, Infectious (46)  ·  Skin and Connective Tissue Diseases (46)  ·  Dermatomycoses (45)  ·  Infections (45)  ·  Skin Diseases (45)  ·  Mycoses (43)  ·  Nail Diseases (30)  ·  Pathological Conditions, Signs and Symptoms (13)  ·  Signs and Symptoms (13)  ·  Skin Manifestations (13)  ·  Foot Dermatoses (12)  ·  Foot Diseases (12)  ·  Pruritus (12)

Interventions

Terbinafine (5)  ·  tavaborole (5)  ·  1-(2-(2,4-dichlorophenyl)-2-(4-(trifluoromethyl)benzyloxy)ethyl)-1H-imidazole (2)  ·  Nitric Oxide (2)  ·  VT-1161 (2)  ·  Albendazole (1)  ·  Econazole (1)  ·  Exercise (1)  ·  Itraconazole (1)  ·  Ketoconazole (1)  ·  Miconazole (1)  ·  Nitrogen (1)  ·  Oxygen (1)  ·  Separase (1)  ·  Water (1)

Sponsors

Pfizer (7)  ·  Nitric BioTherapeutics, Inc (4)  ·  Sun Pharmaceutical Industries, Inc. (2)  ·  Topica Pharmaceuticals (2)  ·  Viamet (2)  ·  Abeona Therapeutics, Inc (1)  ·  Almirall, S.A. (1)  ·  AmDerma (1)  ·  Bayer (1)  ·  Blueberry Therapeutics (1)  ·  Celtic Pharma Development Services (1)  ·  DermBiont, Inc. (1)  ·  Dow Pharmaceutical Sciences (1)  ·  Galeno Desenvolvimento de Pesquisas Clínicas (1)  ·  Gilberto De Nucci (1)

Countries

United States (24)  ·  Canada (8)  ·  Germany (4)  ·  Mexico (4)  ·  Dominican Republic (2)  ·  Brazil (1)  ·  Czechia (1)  ·  Iceland (1)  ·  India (1)  ·  Poland (1)  ·  Puerto Rico (1)  ·  Saint Kitts and Nevis (1)  ·  Sweden (1)

Top investigators

Aditya Gupta, MD,PhD (1)  ·  Alicia Barba, MD (1)  ·  Alicia Bucko, DO (1)  ·  Bernard Goffe, MD (1)  ·  Boni Elewski, MD (1)  ·  Brock McConnehey,, DO (1)  ·  Carl Schanbacher, MD (1)  ·  Charles Lynde, MD (1)  ·  Christoph Willers, MD, MBA (1)  ·  Dan Stewart, DO (1)  ·  Daniel G. Lorch, MD (1)  ·  David Bolshoun, MD (1)

Results publications

PMID 21967490, PMID 23377392, PMID 30526582, PMID 32421854, PMID 39624747

NIH funding

2008 (1), 2009 (1)